157528-56-8

Basic information

• Product Name: (R)-1-Benzyl-3-pyrrolidinecarbonitrile
• Synonyms: (R)-1-Benzyl-3-pyrrolidinecarbonitrile;(R)-1-BENZYL-PYRROLIDINE-3-CARBONITRILE;(R)-1-Benzyl-3-pyrrolidinecarbonitrile;EOS-61264
• CAS NO: 157528-56-8
• Molecular Formula: C₁₂H₁₄N₂
• Molecular Weight: 186.253
• Mol File: 157528-56-8.mol

Chemical Properties

• Boiling Point: 313.3°C at 760 mmHg
• Flash Point: 132.8°C
• Appearance: /
• Density: 1.08g/cm3
• Vapor Pressure: 0.0005mmHg at 25°C
• Refractive Index: 1.5340-1.5380
• Storage Temp.: 0-10°C
• CAS DataBase Reference: (R)-1-Benzyl-3-pyrrolidinecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-Benzyl-3-pyrrolidinecarbonitrile(157528-56-8)
• EPA Substance Registry System: (R)-1-Benzyl-3-pyrrolidinecarbonitrile(157528-56-8)

Safety Data

• Hazardous Substances Data: 157528-56-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Compounds Synthesis:
(R)-1-Benzyl-3-pyrrolidinecarbonitrile is used as a precursor in the synthesis of various pharmaceutical compounds, specifically targeting the development of drugs with anti-inflammatory and anti-cancer properties. Its unique structure and chirality make it a valuable component in creating effective and targeted medications.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (R)-1-Benzyl-3-pyrrolidinecarbonitrile serves as a key intermediate. It is instrumental in the research and development of new chemical entities that hold potential for therapeutic use, contributing to the advancement of medical treatments and interventions.
Used in Drug Development:
(R)-1-Benzyl-3-pyrrolidinecarbonitrile is also utilized in drug development, where it plays a crucial role in the creation and optimization of new drugs. Its application in this field is driven by its potential to contribute to the discovery of innovative pharmaceuticals that address a range of health conditions.

InChI:InChI=1/C12H14N2/c13-8-12-6-7-14(10-12)9-11-4-2-1-3-5-11/h1-5,12H,6-7,9-10H2/t12-/m0/s1

Upstream product

• 10442-39-4 tetra-n-butylammonium cyanide 
• 118354-71-5 (S)-methanesulfonic acid 1-benzylpyrrolidin-3-yl ester 
• 143-33-9 sodium cyanide 
• 908598-98-1 (R)-2-Dibenzylamino-butane-1,4-diol 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 

Downstream Products

• 1212293-24-7 (R)-1-Benzyl-pyrrolidine-3-carboxylic acid; hydrochloride 
• 115687-29-1 (R)-1-Benzyl-pyrrolidine-3-carboxylic acid amide 
• 922718-09-0 1-cyclopropyl-7-fluoro-9-methyl-8-{3-[1-(methylpiperidin-4-ylamino)cyclopropyl]pyrrolidin-1-yl}-4-oxo-4H-quinolizine-3-carboxylic acid 
• 351362-84-0 1-((R)-methyl-1-pyrrolidin-3-yl)-ethylamine 
• 157528-57-9 (R)-3-(1-amino-1-methylethyl)-1-benzylpyrrolidine 
• 303111-45-7 2-((R)-1-Benzyl-pyrrolidin-3-yl)-ethylamine 
• 303111-44-6 ((S)-1-Benzyl-pyrrolidin-3-yl)-acetonitrile 
• 303111-43-5 (R)-(+)-1-(phenylmethyl)-3-hydroxymethylpyrrolidine 
• 216311-59-0 methyl (R)-(-)-1-(phenylmethyl)-3-pyrrolidinecarboxylate 
• 229323-07-3 (R)-C-(1-benzyl-pyrrolidin-3-yl)-methylamine 

Relevant articles and documents

Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections

The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can

The design and discovery of novel amide CCR5 antagonists

The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential.

8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS

The invention provides compound and salts of Formula (I) and (II), disclosed herein, which includes compounds of Formula (A) and Formula (B) such compounds possess useful antimicrobial activity. The variables R2, R3, R5, R

INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES

The present invention provides intermediates needed for production of an optically active compound represented by formula (6), which enable the compound (6) to be readily synthesized in simple production steps without optical resolution, and also provides

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I) wherein A is formula (II), formula (III) or formula (IV), and B is formula (V), formula (VI), or formula (VII), can be used in a variety of applications including use as antibacterial agents.

ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES

Compounds of formula (I) wherein: A is Formula (II), Formula (III), or Formula (IV) and B is Formula (V), Formula (VI), or Formula (VII), can be used in a variety of applications including use as antibacterial agents.

A practical ex-chiral-pool synthesis of β-proline and homo-β-proline

Starting from aspartic acid an efficient synthesis of enantiomerically pure β-proline and homo-β-proline is described. The key step of the synthesis includes formation of the 1,4-biselectrophile 6, followed by rearrangement via the aziridinium intermediate 7 and ring closure to give the pyrrolidinium salt 9a which can serve as a common precursor for both target compounds.

An Efficient Method for the Synthesis of (R)-3-(1-Amino-1-methylethyl)pyrrolidines for the Antiinfective Agent, PD 138312

Methylcerium dichloride has been found to undergo bis addition to nitriles to produce tertiary carbinamines with retention of optical purity at the ? position.This result is used in the development of a short, economical synthesis of the 1,8-naphthyridine antiinfective agent, PD 138312.

Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines

The process for the preparation of chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines used as key intermediates for the preparation of naphthyridine and quinolone antibacterial agents which comprises reacting readily available chiral 1-subst